2 weeks Ago By ABMN Staff
GlycoMimetics, Inc. ( NASDAQ:GLYC – Get Free Report ) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,820,000 shares, a drop of 5.
7% from the August 31st total of 1,930,000 shares. Based on an average trading volume of 3,640,000 shares, the short-interest ratio is currently 0.5 days.
Wall Street Analysts Forecast Growth GLYC has been the topic of several research reports. TD Cowen lowered shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. StockNews.
com initiated coverage on GlycoMimetics in a report on Friday. They set a “sell” rating on the stock. Finally, HC Wainwright reissued a “neutral” rating on shares of GlycoMimetics in a report on Tuesday, June 4th.
View Our Latest Research Report on GLYC Insider Activity Institutional Inflows and Outflows Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in GlycoMimetics by 14.
0% in the first quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock valued at $8,286,000 after purchasing an additional 340,112 shares during the last quarter.
Acadian Asset Management LLC raised its stake in GlycoMimetics by 61.8% during the second quarter. Acadian Asset Management LLC now owns 534,753 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 204,227 shares during the period.
Finally, Renaissance Technologies LLC boosted its holdings in shares of GlycoMimetics by 483.5% in the 2nd quarter. Renaissance Technologies LLC now owns 826,851 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 685,151 shares during the last quarter.
75.19% of the stock is currently owned by institutional investors and hedge funds. GlycoMimetics Price Performance Shares of NASDAQ GLYC opened at $0.
17 on Tuesday. The company has a 50-day simple moving average of $0.19 and a 200-day simple moving average of $0.
80. The company has a market cap of $10.89 million, a PE ratio of -0.
29 and a beta of 2.07. GlycoMimetics has a 12 month low of $0.
16 and a 12 month high of $3.53. GlycoMimetics Company Profile ( Get Free Report ) GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. Featured Articles Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter .
.
